**MITF**

The *MITF* gene is an oncogene. Oncogenes are involved in cell growth. When they don't work properly, cells can grow out of control, which can lead to cancer. The primary role of *MITF* is to control melanocytes, the cells that make skin pigment.

Like most genes, each person has two copies of the *MITF* gene: one inherited from each parent. A mutation in a single *MITF* gene inherited from either parent is known to increase risk of melanoma and kidney cancer.

Certain factors can greatly increase risk of melanoma, including an individual's geographic region, ethnicity and sun exposure. For example, melanoma is 20 times more common in Caucasians than it is in African Americans.\(^1\) The risk of kidney cancer also varies depending on whether a person has a history of smoking cigarettes or exposure to certain substances and chemicals.\(^2\)

**How common are mutations in the *MITF* gene?**

Mutations in the *MITF* gene are rare—the exact frequency is not yet known. Studies to establish the frequency of *MITF* mutations are ongoing.

**How mutations in this gene impact risk**

**Women**

If a woman has a mutation in the *MITF* gene, her chances of developing melanoma and kidney cancer are greater than that of the average US woman. This does not mean that she has a diagnosis of cancer or that she will definitely develop cancer in her lifetime.

<table>
<thead>
<tr>
<th>Cancer by age 95</th>
<th>Average US woman(^3)</th>
<th>With <em>MITF</em> mutation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Melanoma</td>
<td>1.6%</td>
<td>Elevated(^4)</td>
</tr>
<tr>
<td>Kidney</td>
<td>1.2%</td>
<td>Elevated(^4)</td>
</tr>
</tbody>
</table>

---


Men
If a man has a mutation in the MITF gene, his chances of developing melanoma and kidney cancer are greater than that of the average US man. This does not mean that he has a diagnosis of cancer or that he will definitely develop cancer in his lifetime.

<table>
<thead>
<tr>
<th>Cancer by age 95</th>
<th>Average US man</th>
<th>With MITF mutation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Melanoma</td>
<td>2.6%</td>
<td>Elevated&lt;sup&gt;4&lt;/sup&gt;</td>
</tr>
<tr>
<td>Kidney</td>
<td>2%</td>
<td>Elevated&lt;sup&gt;4&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

Additional information
Not all MITF mutations are linked to increased cancer risk.
For MITF, only chr3:g.70014091 (including c.952G>A) is analyzed, because other positions are not known to impact cancer risk.

Screening guidelines
Below is a summary of screening guidelines from the American Cancer Society (ACS). Because there are no published screening guidelines specific to individuals with MITF mutations, these guidelines are for individuals who have the same risk of melanoma as the average US individual. If you have a mutation in this gene, your healthcare provider may use these ACS Guidelines to help create a customized screening plan for you. They might also make additional recommendations to reduce your risk of melanoma.

Women and Men
Melanoma<sup>5</sup>
- Your healthcare provider may discuss skin exams and eye exams for melanoma screening.
- To reduce the chance of developing melanoma, the American Cancer Society recommends limiting exposure to UV light by avoiding excess sun exposure, wearing a hat, sunglasses and long protective clothing, applying sunscreen with SPF of 30 or higher and avoiding tanning beds and sun lamps.

---
• Any new, unusual, or changing moles should be reported to your provider or dermatologist.

Kidney cancer
• Currently, there are no kidney cancer screening guidelines specific to MITF mutation carriers. Your provider may discuss screening or referral to a specialist.

Useful resources
American Melanoma Foundation
An organization supporting melanoma research, and providing advocacy and public awareness of melanoma.
www.melanomafoundation.org

Kintalk
An educational and family communication site for individuals and their families with hereditary cancer conditions.
www.kintalk.org

Last updated May 15, 2017